Media
Follow our progress and stay up to date with our press releases and media coverage.
Press Releases
GeneVentiv Announces Appointment to Scientific Advisory Board
January 12, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the...
Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia
GeneVentiv Therapeutics and University of North Carolina Chapel Hill Enter License Agreement RALEIGH, NC, November 2, 2020 — GeneVentiv Therapeutics, Inc. has entered into a license agreement with the University of North Carolina Chapel Hill for a patent pending, gene...
In the News
UNC Gene Therapy Spinoff Aims to Cure Hemophilia
Latest spinoff from UNC’s Gene Therapy Center wants to find a cure for hemophilia Read more here: https://www.newsobserver.com/news/business/article247379109.html#storylink=cpy RALEIGH UNC-Chapel Hill’s gene therapy center has birthed yet another startup in the...
New UNC spin-out targets hemophilia cure through gene therapy
By Seth Thomas Gulledge – Staff Writer, Triangle Business Journal - November 4, 2020 Companies in this article: University of North Carolina at Chapel Hill https://www.unc.edu/, GeneVentiv Therapeutics https:/www.geneventiv.com A new company launching around...
Raleigh’s GeneVentiv Therapeutics signs deal with UNC for potential hemophilia therapy
by Meredith Dockery, North Carolina Business News Wire — November 4, 2020 . RALEIGH — GeneVentiv Therapeutics, Inc., a gene therapy developer, announced a license agreement with the University of North Carolina at Chapel Hill for a patent-pending, gene therapy for...
UNC Spinout GeneVentiv’s Gene Therapy offers a Universal Cure for Hemophilia
November 2, 2020 RALEIGH, NC – GeneVentiv Therapeutics has entered a license agreement with University of North Carolina Chapel Hill for a gene therapy that is a universal cure for Hemophilia A or B patients with or without inhibitors to their missing clotting...